PE20150616A1 - Composicion que comprende factores de crecimiento obtenidos a partir del plasma sanguineo - Google Patents

Composicion que comprende factores de crecimiento obtenidos a partir del plasma sanguineo

Info

Publication number
PE20150616A1
PE20150616A1 PE2015000116A PE2015000116A PE20150616A1 PE 20150616 A1 PE20150616 A1 PE 20150616A1 PE 2015000116 A PE2015000116 A PE 2015000116A PE 2015000116 A PE2015000116 A PE 2015000116A PE 20150616 A1 PE20150616 A1 PE 20150616A1
Authority
PE
Peru
Prior art keywords
growth factors
composition
blood plasma
composition including
including growth
Prior art date
Application number
PE2015000116A
Other languages
English (en)
Spanish (es)
Inventor
Aldecoa Eduardo Anitua
Original Assignee
Biotechnology Inst I Mas D Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49111229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotechnology Inst I Mas D Sl filed Critical Biotechnology Inst I Mas D Sl
Publication of PE20150616A1 publication Critical patent/PE20150616A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PE2015000116A 2012-08-09 2013-07-19 Composicion que comprende factores de crecimiento obtenidos a partir del plasma sanguineo PE20150616A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.

Publications (1)

Publication Number Publication Date
PE20150616A1 true PE20150616A1 (es) 2015-05-25

Family

ID=49111229

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000116A PE20150616A1 (es) 2012-08-09 2013-07-19 Composicion que comprende factores de crecimiento obtenidos a partir del plasma sanguineo

Country Status (17)

Country Link
US (2) US20140044795A1 (https=)
EP (1) EP2883569B1 (https=)
JP (1) JP6339568B2 (https=)
KR (1) KR102149162B1 (https=)
CN (1) CN104519961A (https=)
AR (1) AR092086A1 (https=)
BR (1) BR112015002760A2 (https=)
CA (1) CA2881075A1 (https=)
CL (1) CL2014003510A1 (https=)
CO (1) CO7170177A2 (https=)
ES (2) ES2442242B1 (https=)
IN (1) IN2014MN02675A (https=)
MX (1) MX357828B (https=)
PE (1) PE20150616A1 (https=)
RU (1) RU2696497C2 (https=)
TW (1) TWI649084B (https=)
WO (1) WO2014023860A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
AR022333A1 (es) * 1999-01-26 2002-09-04 Anitua Aldecoa Eduardo Regenerador de tejido oseo
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
ES2221770B2 (es) 2002-04-19 2006-07-16 Eduardo Anitua Aldecoa Metodo de preparacion de un compuesto para la regeneracion de tejidos.
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
EP2152240A4 (en) * 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
MX2011011921A (es) 2009-05-14 2011-12-06 Biotechnology Inst I Mas D Sl Metodo para la preparacion de al menos un compuesto a partir de sangre, y dispositivo de extraccion para ser utilizado en la ejecucion de dicho metodo.
KR101114712B1 (ko) * 2009-10-23 2012-02-29 세원셀론텍(주) 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법
ES2369945B1 (es) 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.

Also Published As

Publication number Publication date
WO2014023860A1 (es) 2014-02-13
MX2015001677A (es) 2015-04-10
EP2883569A1 (en) 2015-06-17
CL2014003510A1 (es) 2015-05-04
IN2014MN02675A (https=) 2015-08-28
ES2442242B1 (es) 2014-11-25
TWI649084B (zh) 2019-02-01
BR112015002760A2 (pt) 2020-04-22
EP2883569B1 (en) 2017-12-20
ES2442242A1 (es) 2014-02-10
ES2662385T3 (es) 2018-04-06
KR102149162B1 (ko) 2020-08-31
JP2015524464A (ja) 2015-08-24
MX357828B (es) 2018-07-25
TW201408310A (zh) 2014-03-01
AR092086A1 (es) 2015-03-25
RU2015104076A (ru) 2016-09-27
US20140044795A1 (en) 2014-02-13
JP6339568B2 (ja) 2018-06-06
CA2881075A1 (en) 2014-02-13
CN104519961A (zh) 2015-04-15
CO7170177A2 (es) 2015-01-28
KR20150040860A (ko) 2015-04-15
RU2696497C2 (ru) 2019-08-02
US20160184360A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2015012644A (es) Tratamiento de cataplejia.
UA110813C2 (uk) Лікування ліподистрофії
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
CL2014001339A1 (es) Procedimiento de preparacion de un compuesto intermediario derivado de 5-fluoro-1h-pirazolopiridina; compuestos intermediarios que participan del mismo y formas cristalinas del compuesto final obtenido, el cual es util en el tratamiento de trastornos cardiocirculatorios.
IT1405680B1 (it) Processo per la produzione di l-fucosio.
UA115231C2 (uk) Сполуки імідазопіролідинонів
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PE20151519A1 (es) Composicion de liposoma
CL2015000543A1 (es) Derivados de alcanediil y alcanediil-c17, de ácido oleanólico compuestos intermediarios, composición parmacéutica y métodos asociados.
GT201400111A (es) Triazolopiridinas sustituidas
BR112014007203A2 (pt) composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
GT201400022A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
AR093716A1 (es) Composicion de cuidado oral
BR112015007196A2 (pt) processos em fase de solução para a fabricação de depsipeptídeos e novos intermediários
MX353743B (es) Metodo de tratamiento fungicida y/o bactericida de cepas resistentes por medio de uno o mas aceites esenciales.
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
BR112014010278A2 (pt) método de erradicar espécies indesejáveis de uma zona de tratamento, composição fumigante, e método de fazer uma composição fumigante
CL2013000688A1 (es) Procedimiento para obtener una composicion de igg a partir de una composicion de igg parcialmente purificada.

Legal Events

Date Code Title Description
FC Refusal